Patient and disease characteristics according to POD24 status
| . | GLSG . | BCCA . | ||||
|---|---|---|---|---|---|---|
| . | POD24 . | No POD24 . | P . | POD24 . | no POD24 . | P . |
| No. of evaluable patients | 23 | 109 | 23 | 79 | ||
| First-line treatment | R-CHOP (151/151, 100%) | R-CVP (107/107, 100%) | ||||
| Maintenance treatment by ITT | IFN (151/151, 100%) | Rituximab (93/107, 87%) | ||||
| Median follow-up in years | 8.4 | 8.2 | 7.1 | 6.7 | ||
| Age (y), median (range) | 61 (27-74) | 56 (29-77) | .195 | 62 (43-83) | 61 (37-83) | .398 |
| Male gender | 11/23 (48%) | 55/109 (50%) | >.99 | 15/23 (65%) | 42/79 (53%) | .618 |
| High-risk FLIPI | 18/23 (78%) | 48/109 (44%) | .0059 | 16/23 (70%) | 33/79 (42%) | .035 |
| Age >60 y | 12/23 (52%) | 39/109 (36%) | .218 | 12/23 (52%) | 42/79 (53%) | >.99 |
| No. of nodal sites >4 | 19/23 (83%) | 71/109 (65%) | .165 | 20/23 (87%) | 55/79 (70%) | .164 |
| LDH elevated | 11/23 (48%) | 31/109 (28%) | .117 | 6/21 (29%) | 15/77 (19%) | .548 |
| Hb <120 g/L | 10/23 (43%) | 17/109 (16%) | .0064 | 4/21 (19%) | 7/79 (9%) | .350 |
| ECOG-PS ≥2 | 0/23 (0%) | 5/109 (5%) | .655 | 6/23 (26%) | 9/79 (11%) | .157 |
| . | GLSG . | BCCA . | ||||
|---|---|---|---|---|---|---|
| . | POD24 . | No POD24 . | P . | POD24 . | no POD24 . | P . |
| No. of evaluable patients | 23 | 109 | 23 | 79 | ||
| First-line treatment | R-CHOP (151/151, 100%) | R-CVP (107/107, 100%) | ||||
| Maintenance treatment by ITT | IFN (151/151, 100%) | Rituximab (93/107, 87%) | ||||
| Median follow-up in years | 8.4 | 8.2 | 7.1 | 6.7 | ||
| Age (y), median (range) | 61 (27-74) | 56 (29-77) | .195 | 62 (43-83) | 61 (37-83) | .398 |
| Male gender | 11/23 (48%) | 55/109 (50%) | >.99 | 15/23 (65%) | 42/79 (53%) | .618 |
| High-risk FLIPI | 18/23 (78%) | 48/109 (44%) | .0059 | 16/23 (70%) | 33/79 (42%) | .035 |
| Age >60 y | 12/23 (52%) | 39/109 (36%) | .218 | 12/23 (52%) | 42/79 (53%) | >.99 |
| No. of nodal sites >4 | 19/23 (83%) | 71/109 (65%) | .165 | 20/23 (87%) | 55/79 (70%) | .164 |
| LDH elevated | 11/23 (48%) | 31/109 (28%) | .117 | 6/21 (29%) | 15/77 (19%) | .548 |
| Hb <120 g/L | 10/23 (43%) | 17/109 (16%) | .0064 | 4/21 (19%) | 7/79 (9%) | .350 |
| ECOG-PS ≥2 | 0/23 (0%) | 5/109 (5%) | .655 | 6/23 (26%) | 9/79 (11%) | .157 |
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; Hb, hemoglobin; IFN, interferon-α; ITT, intention-to-treat; LDH, lactate dehydrogenase; POD24, progression of disease within 24 months; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone.